<DOC>
	<DOCNO>NCT01634763</DOCNO>
	<brief_summary>Estimation Maximum tolerate dose ( MTD ) and/or Recommended dose ( RD ) LDK378 single agent administer orally Japanese patient tumor characterize genetic alteration anaplastic lymphoma kinase ( ALK )</brief_summary>
	<brief_title>Study Safety Preliminary Efficacy LDK378 Japanese Patients With Genetic Alterations Anaplastic Lymphoma Kinase ( ALK )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>Patients locally advance metastatic malignancy progress despite standard therapy , effective standard therapy exist Only patient tumor characterize genetic alteration ALK . For nonsmall cell lung cancer ( NSCLC ) , ALK translocation must detect Fluorescent situ hybridization ( FISH ) ≥15 % tumor cell . Local site document result ALK alteration acceptable enrollment patient . Central confirmation local result require . Eastern Cooperative Oncology Group ( ECOG ) performance status grade ≤ 2 Adequate organ function Doseexpansion part : Patients must NSCLC progress since prior therapy alectinib . Alectinib must prior ALK inhibitor receive patient prior trial entry . Patients symptomatic Central Nerve System ( CNS ) metastases neurologically unstable require increase dos steroid control CNS disease Patients unresolved nausea , vomit diarrhea &gt; Common Terminology Criteria Adverse Events ( CTCAE ) grade 1 Other concurrent severe and/or uncontrolled medical condition Patients treat chemotherapy biologic therapy investigational agent &lt; 2 week prior start daily dose study drug compound halflife ≤ 3 day , &lt; 4 week prior start daily dose study drug compound prolonged halflife ( &lt; 6 week patient receive nitrosoureas mitomycinC ) Unresolved toxicity great CTCAE grade 1 unstable toxicity previous anticancer therapy radiotherapy ( exclude neurotoxicity , alopecia , ototoxicity , lymphopenia ) , incomplete recovery previous surgery , unless agree Novartis Principal Investigator document Patients receive radiotherapy lung within 4 week prior start daily dose study drug patient recover radiotherapyrelated toxicity . For anatomic site radiotherapy large volume ( include whole brain radiotherapy ) &lt; 2 week prior start daily dose study drug , patient receive radiotherapy small volume ( include stereotactic radiotherapy CNS ) &lt; 3 day prior start study drug . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Phase I , open-label , dose escalation , oral LDK378 , Japanese patient tumor characterize ALK genetic alteration</keyword>
</DOC>